Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opexa Therapeutics (OPXA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,132
  • Shares Outstanding, K 7,660
  • Annual Sales, $ 2,910 K
  • Annual Income, $ -7,980 K
  • 36-Month Beta 2.20
  • Price/Sales 1.69
  • Price/Cash Flow 0.00
  • Price/Book 1.69
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.89
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/11/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.62 +12.90%
on 04/18/17
0.86 -18.60%
on 03/28/17
-0.07 (-9.09%)
since 03/24/17
3-Month
0.62 +12.90%
on 04/18/17
1.26 -44.44%
on 02/15/17
-0.26 (-27.08%)
since 01/25/17
52-Week
0.50 +40.00%
on 11/15/16
4.93 -85.80%
on 08/24/16
-1.67 (-70.46%)
since 04/25/16

Most Recent Stories

More News
Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics

For today, Stock-Callers.com takes a closer look at some Biotech equities: Cara Therapeutics Inc. (NASDAQ: CARA), Heat Biologics Inc. (NASDAQ: HTBX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Opexa...

CARA : 16.38 (-1.38%)
HTBX : 0.79 (+1.28%)
VNDA : 14.93 (+1.22%)
OPXA : 0.70 (+4.48%)
Global Autologous Cell Therapy Market: Development of Bone Marrow-based Products Ensures Whopping 21.9% CAGR by 2024, Observes TMR

The leading players operating in the Global Autologous Cell Therapy Market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co.,...

BCLI : 4.08 (-0.97%)
VCEL : 2.60 (-1.89%)
OPXA : 0.70 (+4.48%)
Opexa Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

THE WOODLANDS, TX / ACCESSWIRE / November 14, 2016 / Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today reported...

OPXA : 0.70 (+4.48%)
Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary Progressive Multiple Sclerosis

THE WOODLANDS, TX / ACCESSWIRE / November 2, 2016 / Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS)...

OPXA : 0.70 (+4.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a...

See More

Support & Resistance

2nd Resistance Point 0.75
1st Resistance Point 0.71
Last Price 0.70
1st Support Level 0.63
2nd Support Level 0.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.